Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

Bruce Ettinger, MD;Preeta Chidambaran, MD;Alice Pressman, MS;

Publication

Article

June 1, 2001

The American Journal of Managed Care

June 2001

Volume7

Issue 6

Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

Author(s):

Bruce Ettinger, MD,Preeta Chidambaran, MD

Download PDF: Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

Articles in this issue

Health Plan's Use of Asthma Quality Improvement Projects to Meet NCQA Accreditation Standards

Does the HEDIS Asthma Measure Go Far Enough?

Diagnosis and Care of Irritable Bowel Syndrome in a Community-Based Population

Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

Effect of Rofecoxib Therapy on Measures of Health-Related Quality of Life in Patients with Osteoarthritis

Rheumatoid Arthritis: Guidelines for Emerging Therapies

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

September 4th 2025

Managed Care Reflections: A Q&A With Dora Hughes, MD, MPH

Dora Hughes, MD, MPH Christina Mattina

September 4th 2025

Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending

Amber K. Sabbatini, MD, MPH David B. Muhlestein, PhD, JD Canada Parrish, PhD, MSPH Laura G. Burke, MD Kathleen Y. Li, MD, MSc Michelle P. Lin, MD, MSc

September 4th 2025

More Employers Offer Preventive Drug Lists Over Time

Anita K. Wagner, PharmD, DrPH, MPH Stephanie Argetsinger, MS, MPH Matt Lakoma, MPH Jenna Clemenzi, MPP Fang Zhang, PhD J. Frank Wharam, MD, MPH Dennis Ross-Degnan, ScD

September 4th 2025

Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns

Maria Ukhanova, MD, PhD Joseph S. Wozny, MPH Chau N. Truong, PhD Lopita Ghosh, MBA Trudy M. Krause, DrPH

September 4th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH

September 4th 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

Related Content

September 4th 2025

Managed Care Reflections: A Q&A With Dora Hughes, MD, MPH

Dora Hughes, MD, MPH Christina Mattina

September 4th 2025

Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending

Amber K. Sabbatini, MD, MPH David B. Muhlestein, PhD, JD Canada Parrish, PhD, MSPH Laura G. Burke, MD Kathleen Y. Li, MD, MSc Michelle P. Lin, MD, MSc

September 4th 2025

More Employers Offer Preventive Drug Lists Over Time

Anita K. Wagner, PharmD, DrPH, MPH Stephanie Argetsinger, MS, MPH Matt Lakoma, MPH Jenna Clemenzi, MPP Fang Zhang, PhD J. Frank Wharam, MD, MPH Dennis Ross-Degnan, ScD

September 4th 2025

Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns

Maria Ukhanova, MD, PhD Joseph S. Wozny, MPH Chau N. Truong, PhD Lopita Ghosh, MBA Trudy M. Krause, DrPH

September 4th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

September 4th 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

Newsletter